CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

doi:10.1038/nature07179

Nature. Author manuscript; available in PMC 2009 September 25.

Published in final edited form as:

Nature. 2008 September 25; 455(7212): 547–551.

Published online 2008 September 14. doi: 10.1038/nature07179

PMCID: PMC2587138

NIHMSID: NIHMS58283

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

Ron Firestein,^1,^3,^6,⁷ Adam J. Bass,^1,^4,^6,⁷ So Young Kim,^1,^4,^6,⁷ Ian F. Dunn,^1,^2,^6,⁷ Serena J. Silver,⁷ Isil Guney,^1,^6,⁷ Ellen Freed,¹ Azra H. Ligon,³ Natalie Vena,¹ Shuji Ogino,^1,³ Milan G. Chheda,^1,^5,⁷ Pablo Tamayo,⁷ Stephen Finn,³ Yashaswi Shrestha,^1,^6,⁷ Jesse S. Boehm,⁷ Supriya Jain,¹ Emeric Bojarski,¹ Craig Mermel,^1,^6,⁷ Jordi Barretina,^1,^6,⁷ Jennifer A. Chan,^3,⁷ Jose Baselga,⁸ Josep Tabernero,⁸ David E. Root,⁸ Charles S. Fuchs,¹ Massimo Loda,^1,³ Ramesh A. Shivdasani,^1,⁴ Matthew Meyerson,^1,^3,^6,⁷ and William C. Hahn^1,^4,^6,⁷

¹Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 U.S.A.

²Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 U.S.A.

³Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 U.S.A.

⁴Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 U.S.A.

⁵Department of Neuro-oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 U.S.A.

⁶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 U.S.A.

⁷Broad Institute of Harvard and M.I.T., 7 Cambridge Center, Cambridge, MA 02142 U.S.A.

⁸Department of Medical Oncology, Hospital Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain.

Correspondence and Requests for materials should be addressed to W.C.H. (Email: william_hahn/at/dfci.harvard.edu).

The publisher's final edited version of this article is available at Nature

See other articles in PMC that cite the published article.

Abstract

Aberrant activation of the canonical Wnt/β-catenin pathway occurs in almost all colorectal cancers and contributes to their growth, invasion and survival. Although dysregulated β-catenin activity drives colon tumorigenesis, additional genetic perturbations are required to elaborate fully malignant disease. To identify genes that both modulate β-catenin activity and are essential for colon cancer cell proliferation, we conducted two loss-of-function screens in human colon cancer cells and compared genes identified in these screens with an analysis of copy-number alterations in colon cancer specimens. One of these genes, CDK8, which encodes a member of the mediator complex, is located at 13q12.13, a region of recurrent copy number gain in a substantial fraction of colon cancers. Suppression of CDK8 expression inhibited proliferation in colon cancer cells characterized by high levels of CDK8 and β-catenin hyperactivity. CDK8 kinase activity was necessary for β-catenin driven transformation and expression of several β-catenin transcriptional targets. Together these observations suggest that therapeutic interventions targeting CDK8 may confer clinical benefit in β-catenin-driven malignancies.

The Wnt/β-catenin pathway is implicated in over 90% of colon cancers and in a fraction of other human malignancies. Loss of the tumor suppressor APC or activating CTNNB1 (β-catenin) mutations results in constitutive activity of the β-catenin-T cell factor (TCF) transcriptional complex, which drives adenoma formation¹^,². Although mutations in TP53 or K-RAS cooperate with dysregulated β-catenin signaling to program a fully malignant phenotype³, these mutations are found in less than half of β-catenin-driven colon cancers⁴.

To identify oncogenes that modulate β-catenin-dependent transcription and regulate colon cancer cell proliferation, we conducted two RNAi-based loss-of-function screens. We engineered DLD1 colon cancer cells, which harbor APC deletions and depend on β-catenin for proliferation⁵, to stably express “TOPFLASH” β-catenin-luciferase and “FOPFLASH” mutant-Renilla reporter constructs⁶^,⁷ (DLD1^Rep). Suppression of β-catenin expression in DLD1^Rep cells by three β-catenin-specific short hairpin RNAs (shRNA) markedly reduced the TOPFLASH/FOPFLASH ratio (Fig. 1a), confirming that reporter activity requires β-catenin expression. We then screened DLD1^Rep cells with a shRNA library containing 4849 shRNAs that target 1000 genes, including 95% of the human kinome⁶. We found 34 genes whose expression was necessary for β-catenin activity, including two known β-catenin regulators, CSNK1G3⁸ and CSNK1E⁹ (Fig. 1b and Supplementary Table 1).

Figure 1

RNAi screens to identify genes essential for colon cancer cell proliferation and β-catenin activity

In parallel, we performed an arrayed, kinase-enriched shRNA screen in another β-catenin-dependent colon cancer cell line, HCT116, to identify genes essential for cancer cell proliferation. We identified 166 candidate genes necessary for proliferation using the criteria that at least two shRNAs targeting the same gene induced a decrease in proliferation. Among the genes identified in this screen were the oncogenes KRAS and MYC (Fig. 1c and Supplementary Table 2). Compilation of genes from the two screens revealed nine whose suppression affected both β-catenin transcriptional activity and colon cancer cell proliferation (Fig. 1d).

To determine whether any of these genes are amplified in colon cancers, we used single-nucleotide polymorphism (SNP) arrays and the GISTIC¹⁰^,¹¹ statistical method to conduct a genome-wide analysis of autosomal copy number (CN) alterations in primary resection specimens from 123 human colorectal adenocarcinomas (Fig. 2a). Among the nine genes identified by our RNAi screens, only CDK8 resides within a particularly significant amplicon at 13q12.13-13q12.2 (false discovery rate (FDR) =1×10⁻²⁹) (Fig. 2a). These findings confirm recent reports that a large portion of chromosome 13 is amplified in colon cancers¹²^,¹³. Fifty-eight of 123 (47%) samples harbored this region of CN gain (Fig. 2b and Supplementary Table 3).

Figure 2

Amplification and overexpression of CDK8 defines a subset of colon cancers

To confirm these findings, we performed fluorescence in situ hybridization (FISH), using probes specific for CDK8 and RB1 (chromosome 13 control probe), on a tissue microarray (TMA) carrying 50 evaluable colon cancer specimens. We detected CDK8 CN gain in 31 of 50 (62%) cases. 20 out of these 50 cases exhibited gains in both CDK8 and RB1 indicative of polysomy and consistent with recent observations linking RB/E2F1, β-catenin and CDK8¹⁴. We also found CDK8 amplifications in 7 of these tumors (defined as CDK8:Control ratio ≥2) and low to moderate level CN gain (CDK8:Control ratio >1 and <2) in an additional 4 specimens (Fig. 2c and Supplementary Table 4). Immunohistochemical analysis of CDK8 expression in the same 50 specimens revealed elevated protein levels in 13 of 50 (26%) colon cancer samples, including those that showed CDK8 CN gain (Supplementary Fig. 1 and Supplementary Table 4). These observations indicate that CDK8 is amplified and overexpressed in a substantial fraction of colon cancers.

The minimal region shared by these tumors encompasses 16 annotated genes (Supplementary Fig. 2a). To determine if CDK8 is the primary target of this amplicon, we first assessed expression of these genes in colon cancer cells harboring chromosome 13q CN gain and found that 4 of the genes were not expressed (Supplementary Figure 2b). We suppressed the expression of the remaining 12 genes in four cell lines, two (HT29, COLO-205) that harbor 13q CN gain and two (SW837, T84) that show 13q loss (Supplementary Fig. 3a, b). To analyze the screen results on a per-gene basis in cell lines with either 13q12 CN gain or deletion, we used an adaptation of the GSEA¹⁵ method and found that CDK8 was the only gene in this region required for proliferation of cell lines harboring 13q gain (FDR=0.24) (Fig. 2d and Supplementary Table 5). These observations suggested that colon cancer cells harboring 13q12.2 amplification are particularly dependent on CDK8 expression for proliferation.

We then analyzed CDK8 CN gain and protein expression in a panel of 12 colon cancer lines. Four (COLO-205, HT29, SW1463, and SW480)¹⁶ of these 12 lines were found to harbor CDK8 gain (Supplementary Fig. 3a, b), and these cell lines exhibited the highest levels of CDK8 protein (Fig. 2e). Two additional colon cancer cell lines disomic for CDK8 (DLD1 and HCT116) also exhibited elevated CDK8 protein levels (Fig. 2d and Supplementary Fig.3a, b). Suppression of CDK8 expression induced substantially decreased proliferation in all six cell lines with elevated CDK8 protein levels (Fig. 2f,g) but inhibited proliferation rates in the cell lines with lower CDK8 protein levels to a lesser degree (Fig. 2h,i). Suppressing CDK8 in colon cancer cells reduced the fraction of cells in G1 and S phase, increased the number of aneuploid cells, and dramatically slowed cell proliferation without inducing apoptosis (Supplementary Fig. 4), similar to what was observed upon suppression of β-catenin. These observations demonstrate that colon cancer cells that express elevated CDK8 levels are highly dependent on its expression for proliferation.

To determine if CDK8 induces cell transformation, we overexpressed wild type CDK8 or a previously reported kinase inactive, substitution mutant (D173A; CDK8-KD)¹⁷ in immortal murine fibroblasts (NIH 3T3) (Fig. 3a). CDK8 expression induced focus formation, anchorage-independent colony growth, and tumor formation in immunodeficient animals (Fig. 3b-e), whereas the CDK8-KD mutant failed to transform the cells. These observations confirm that CDK8 is a bona fide oncogene, whose kinase activity is necessary for oncogenic activity.

Figure 3

CDK8 and transformation

To dissect the relationship between CDK8 and β-catenin activity, we measured endogenous β-catenin activity in the 12 cell lines used above. The RKO, COLO-741, HCA-7 and FHC cell lines do not harbor known APC or β-catenin mutations¹⁸^,¹⁹^,²⁰ and, as predicted, exhibited low levels of β-catenin activity. Of these four cell lines, suppression of CDK8 induced a substantial proliferation effect only in COLO-741 (Fig. 2h and Supplementary Fig. 5a). Similarly, of the 12 cell lines tested, the six cell lines with highest CDK8 elevated levels showed a greater dependence on β-catenin for proliferation (Supplementary Fig. 5b).

CDK8 is a cyclin-dependent kinase member of the mediator complex, which couples transcriptional regulators to the basal transcriptional machinery²¹. To explore the role of CDK8 in modulating β-catenin transcriptional activity, we confirmed that suppressing CDK8 with two independent, CDK8-specific shRNAs (shCDK8-1, shCDK8-2) in an additional cell line, SW480, also reduced β-catenin-dependent transcriptional activity (Fig. 4a). CDK8 kinase activity depends on the co-factor Cyclin C²², and we found that Cyclin C knockdown preferentially affected colon cancer cell lines with chromosome 13q gain (Supplementary Fig. 6a, b). To test whether CDK8 kinase activity is required to regulate β-catenin activity, we expressed wild-type CDK8 or CDK8-KD in DLD1^Rep cells carrying a shRNA targeting the 3'-untranslated region, shCDK8-1 and found that only wild-type CDK8 partially rescued the effects of suppressing endogenous CDK8(Supplementary Fig. 6c). These observations demonstrate that the kinase activity of CDK8 is necessary for both CDK8-induced transformation and β-catenin driven transcription.

Figure 4

CDK8 mediates transcription of β-catenin driven downstream target genes

The TCF-β-catenin complex regulates expression of several genes implicated in colon cancer, including MYC²³, Axin2²⁶, and LEF1²⁷. Suppression of CDK8 in DLD1 and COLO-205 cells reduced expression of each of genes (Fig. 4b). In contrast, we failed to observe changes in the expression of Notch or HES-1 (Fig. 4c), previously reported targets of CDK8²⁴. Thus, CDK8 modulates a subset of β-catenin driven genes previously implicated in cancer²³^,²⁵^,²⁶.

We then performed chromatin immunoprecipitation (ChIP) near two verified β-catenin/TCF binding elements (TBE)²⁷ in the MYC promoter, as an example of a β-catenin regulated gene, to test whether CDK8 directly modulates MYC expression at the promoter level. We found CDK8 associated with the MYC promoter (Fig. 4d). We therefore asked if loss of CDK8 binding at the MYC promoter affects the ability of β-catenin to bind at the proximal and distal TBEs. Suppression of CDK8 expression reduced the amount of β-catenin bound to the proximal element within the MYC promoter but had little effect on the amount associated with the distal element (Fig. 4e). These observations implicate CDK8 and the mediator complex²¹ as a direct regulator of β-catenin-driven transcription.

To test whether CDK8 activity is required for β-catenin driven transformation, we expressed the dominantly interfering CDK8-KD mutant²⁸ in transformed NIH-3T3 cells expressing a constitutively active β-catenin mutant (Fig. 3c). Disruption of CDK8 activity inhibited β-catenin driven transformation, whereas a dominantly interfering TCF construct, previously shown to inhibit β-catenin-induced cellular transformation²⁹, only partially abrogated CDK8-mediated transformation (Fig. 3d). These observations suggest that while CDK8 is required for β-catenin mediated transformation, the full capacity of CDK8 to transform cells may extend beyond its ability to activate β-catenin.

In summary, we have used an integrated approach to identify CDK8 as an oncogene in a substantial fraction of colorectal cancers and demonstrate that its kinase activity is essential for its ability to regulate β-catenin dependent transcription and transformation. These observations indicate that CDK8 acts in part by co-activating β-catenin driven transcription in colon cancers characterized by both high CDK8 expression and β-catenin activity. Accordingly, therapeutic interventions that target the CDK8 kinase activity in such cancers may be of clinical value.

Methods Summary

Lentiviral infections were performed using pLKO.1 lentiviral shRNA constructs generated by the RNAi Consortium (TRC)⁶ and are listed in Supplementary Table 6. For high throughput screening, cells infected with lentiviruses were allowed to grow for 4 d (DLD1Rep) or 5 d (HCT116). Suppression of β-catenin activity was defined as the ability of at least one shRNA to decrease activity more than 2 standard deviations (SD) below the Z score. Suppression of proliferation was defined as the capacity for at least one shRNA to decrease proliferation more than 1.5 SD below the mean Z score and at least one additional shRNA targeting the same kinase to decrease proliferation more that 1 SD below the mean Z score. For tissue analyses, a Tissue Microarray (TMA) composed of human colon cancer tissue and matching patient normal colon was subjected to immunohistochemical staining. For FISH, BAC clones were hybridized in dual colors to four-micron TMA sections as follows: the RB1 probe labeled in SpectrumGreen was used as a chromosome 13 control probe and the RP11-726I20 BAC, spanning CDK8, was labeled with SpectrumOrange dUTP (both from Abbott Molecular/Vysis, Inc.).

Supplementary Material

SFig1

Click here to view.^{(2.3M, pdf)}

SFig2

Click here to view.^{(319K, tif)}

SFig3

Click here to view.^{(159K, pdf)}

SFig4

Click here to view.^{(641K, pdf)}

SFig5

Click here to view.^{(109K, pdf)}

SFig6

Click here to view.^{(140K, pdf)}

methods

Click here to view.^{(161K, pdf)}

Acknowledgements

We thank E. Shin for expert technical assistance in immunohistochemistry, M. Miri for assistance with sample collection, and G. Getz for assistance with SNP array analysis. This work was supported in part by a T32 NIH grant (R.F.) and a GI SPORE Career Development Grant #P50CA127003 (R.F.), a Harvard-MIT Clinical Investigator Training Program Fellowship (A.B), Department of Defense Prostate Cancer Postdoctoral Fellowships (I.G, S.Y), Warren-Whitman-Richardson, Hagerty Foundation Research Fellowships (I.D.) and K12 award (M.G.C.). J.B. is a Beatriu de Pinos Fellow of the Departament d'Educació i Universitats de la Generalitat de Catalunya. In accordance with Harvard Medical School guidelines, we disclose that W.C.H., M.M., M.L. and R.A.S. are consultants for Novartis.

The SNP data can be found at: http://research3.dfci.harvard.edu/cdk8colon/index.php

References

1. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311–20. [PubMed]

2. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323–7. [PubMed]

3. Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32. [PubMed]

4. Smith G, et al. Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2002;99:9433–8. [PubMed]

5. van de Wetering M, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111:241–50. [PubMed]

6. Moffat J, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283–98. [PubMed]

7. Korinek V, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275:1784–7. [PubMed]

8. Davidson G, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005;438:867–72. [PubMed]

9. Hino S, Michiue T, Asashima M, Kikuchi A. Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem. 2003;278:14066–73. [PubMed]

10. Beroukhim R, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104:20007–12. [PubMed]

11. Weir BA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–8. [PMC free article] [PubMed]

12. Martin ES, et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res. 2007;67:10736–43. [PubMed]

13. Tsafrir D, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 2006;66:2129–37. [PubMed]

14. Morris EJ,JJ, Y F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Naar AM, Dyson NJ. E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8. Submitted to Nature. 2008 [PMC free article] [PubMed]

15. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. [PubMed]

16. Garraway LA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117–22. [PubMed]

17. Gold MO, Rice AP. Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression. Nucleic Acids Res. 1998;26:3784–8. [PMC free article] [PubMed]

18. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A. 1997;94:10330–4. [PubMed]

19. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130–4. [PubMed]

20. Rowan AJ, et al. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits” Proc Natl Acad Sci U S A. 2000;97:3352–7. [PubMed]

21. Conaway RC, Sato S, Tomomori-Sato C, Yao T, Conaway JW. The mammalian Mediator complex and its role in transcriptional regulation. Trends Biochem Sci. 2005;30:250–5. [PubMed]

22. Tassan JP, Jaquenoud M, Leopold P, Schultz SJ, Nigg EA. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc Natl Acad Sci U S A. 1995;92:8871–5. [PubMed]

23. Sansom OJ, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007;446:676–9. [PubMed]

24. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell. 2004;16:509–20. [PubMed]

25. Yook JI, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006;8:1398–406. [PubMed]

26. Murakami T, et al. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun. 2001;288:8–15. [PubMed]

27. He TC, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–12. [PubMed]

28. Chiang MY, et al. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol Cell Biol. 2006;26:6261–71. [PMC free article] [PubMed]

29. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol. 1999;19:5696–706. [PMC free article] [PubMed]